聚乙二醇干扰素α-2a及聚乙二醇干扰素α-2b治疗慢性乙型肝炎临床研究

摘要

Objective To evaluate the clinical effect and safety of PEG-interferon alpha-2a and PEG-interferon al-pha-2b in chronic hepatitis B. Methods 33 cases of chronic hepatitis B were treated with PEG-interferon alpha-2a and 22 cases with PEG-interferon alpha-2b. During the treatment, indicators such as blood routine, biochemistry indices, virology marks and thyroid function were regularly monitored. Results At week 48 , HBeAg serological conversion rates were 22. 7% and 42. 9% respectively in two groups of PEG-interferon alpha-2a and PEG-interferon alpha-2b. Serum HBV DNA negative rates were 63.6% and 54.5% , respectively. HBV DNA negative rates were 47.6% and 50.0% , respectively in first 12 weeks in HBV DNA negative eases of two groups. At the end of half year follow-up, the recurrence rates of HBV DNA were 14.2% and 16.7% , respectively; HBeAg serological conversion maintained response. In follow-up after discontinuation, HBeAg serological conversion appeared with 1 case and 2 cases,respectively. Conclusion All two groups have the function of immune adjustment and antiviral effect, curative effect is notable. Comparison difference of two groups have no statistical significance. Curative effect of the first 12 weeks may be used to predict indices at the end of the treatment. After discontinuation, PEG-interferon alpha-2a and PEG-interferon alpha-2b keeps sustained response.%目的 探讨聚乙二醇干扰素α-2a(PEG-IFNα-2a)及聚乙二醇干扰素α-2b(PEG-IFNα-2b)治疗慢性乙型肝炎(CHB)的疗效及安全性.方法 用PEG-IFNα-2a治疗33例、PEG-1FNα-2b治疗22例慢性乙型肝炎.治疗期间定期监测血常规、生物化学指标、病毒学标志、甲状腺功能等.结果 治疗48周,PEG-IFNα-2a及PEG-IFNα-2b组HBeAg血清学转换率分别为22.7％、42.9％;血清HBV DNA阴转率分别为63.6％、54.5％,两组HBV DNA阴转病例中12周转阴率分别为47.6％、50.0％.随访半年,HBVDNA复发率分别为14.2％、16.7％,HBeAg血清学转换者维持应答.PEG-IFNα-2a及PEG-IFNα-2b组停药后随访半年内HBeAg 血清学转换分别为l例、2例.结论 聚乙二醇干扰素α-2a及聚乙二醇干扰素α-2b治疗慢性乙型肝炎具有免疫调节和抗病毒双重作用,均疗效显著,两组比较差异无统计学意义.前12周可作为疗效预测指标.停药后具有持续应答效应.